These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 11444650

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ, Watson KE, Talbert RL.
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [Abstract] [Full Text] [Related]

  • 3. Combination niacin and statin therapy in primary and secondary prevention of cardiovascular disease.
    Levy DR, Pearson TA.
    Clin Cardiol; 2005 Jul; 28(7):317-20. PubMed ID: 16075823
    [Abstract] [Full Text] [Related]

  • 4. A Clinical Guide to Combination Lipid-Lowering Therapy.
    Russell C, Sheth S, Jacoby D.
    Curr Atheroscler Rep; 2018 Mar 07; 20(4):19. PubMed ID: 29516190
    [Abstract] [Full Text] [Related]

  • 5. Additional insights on how best to utilize statins.
    Feeman WE.
    J Fam Pract; 2014 Mar 07; 63(3):128. PubMed ID: 24701605
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cardiologists like statins-more than patients do.
    Mitka M.
    JAMA; 2001 Dec 12; 286(22):2799-800. PubMed ID: 11735736
    [No Abstract] [Full Text] [Related]

  • 11. Why do statins reduce cardiovascular disease more than other lipid modulating therapies?
    Schooling CM, Au Yeung SL, Leung GM.
    Eur J Clin Invest; 2014 Nov 12; 44(11):1135-40. PubMed ID: 25252212
    [No Abstract] [Full Text] [Related]

  • 12. Statin therapy: when to think twice.
    Wahawisan J, Tovar JM, Granberry MC.
    J Fam Pract; 2013 Dec 12; 62(12):726-32. PubMed ID: 24340334
    [No Abstract] [Full Text] [Related]

  • 13. Beyond statins: what to expect from add-on lipid regulating therapy?
    Laufs U, Weintraub WS, Packard CJ.
    Eur Heart J; 2013 Sep 12; 34(34):2660-5. PubMed ID: 23832488
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Is aggressive lipid-lowering effective and safe in the older adult?
    LaRosa JC.
    Clin Cardiol; 2005 Sep 12; 28(9):404-7. PubMed ID: 16250262
    [Abstract] [Full Text] [Related]

  • 16. [Part II. Combination statin plus fibrate regimens (free and fixed)].
    Clin Investig Arterioscler; 2016 Jul 12; 28 Suppl 3():11-9. PubMed ID: 27473466
    [No Abstract] [Full Text] [Related]

  • 17. HMG CoA reductase inhibitors (statins) for kidney transplant recipients.
    Navaneethan SD, Perkovic V, Johnson DW, Nigwekar SU, Craig JC, Strippoli GF.
    Cochrane Database Syst Rev; 2009 Apr 15; (2):CD005019. PubMed ID: 19370615
    [Abstract] [Full Text] [Related]

  • 18. Trial clouds use of niacin with a statin.
    Harv Heart Lett; 2011 Aug 15; 21(12):2. PubMed ID: 21991606
    [No Abstract] [Full Text] [Related]

  • 19. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
    Ahmed MH.
    J Cardiovasc Med (Hagerstown); 2010 Nov 15; 11(11):858-60. PubMed ID: 20686417
    [Abstract] [Full Text] [Related]

  • 20. Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance.
    Cooper A, O'Flynn N, Guideline Development Group.
    BMJ; 2008 May 31; 336(7655):1246-8. PubMed ID: 18511800
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.